Renal Failure Clinical Trial
Official title:
Evaluating Patient Safety And Ease Of Use Of A Novel Connection-Assist Device For Peritoneal Dialysis
Verified date | February 2020 |
Source | Peripal AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is estimated that there are currently over 3 million patients receiving dialysis treatment worldwide. With effective pre-dialysis counselling, a majority of patients choose the home-based therapy peritoneal dialysis (PD) but only approximately 11% of prevalent dialysis patients use this modality. Connection-assist devices can overcome the challenges posed by decreased manual dexterity and/or visual acuity, and can allow more patients to be treated with home-based therapies. As part of the CE marking authorization, a connection device has been evaluated for safety and ease of use in a usability study.
Status | Completed |
Enrollment | 24 |
Est. completion date | April 30, 2018 |
Est. primary completion date | March 12, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Fifteen patients and nine carers volunteered in this study, ranging from 23 to 86 years in age and from 0.3 to 24 years in experience in the PD therapy. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NIHR Trauma Management MedTech Co-operative | Birmingham |
Lead Sponsor | Collaborator |
---|---|
Peripal AG | Swiss Federal Institute of Technology, University Hospital Birmingham NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and ease of use of a connection device during a continuous ambulatory peritoneal dialysis | Firstly, a training session introduced the operation of the device. The normal steps of a manual connection and breaking of the frangible is replaced by the levers and the buttons in the device. The connections are thereby done in a 'safe' environment which reduces infection risk. A whole cycle of continuous ambulatory peritoneal dialysis is simulated during each training. Secondly, a break of one hour allowed relaxation and recovery. Thirdly, a test was carried out to determine whether the subject could use the device independently with the aid of a quick start guide and the device manual. The training consisted of two cycles in which the moderator guided the subject and three cycles in which the subject guided the moderator through the complete handling of the device. Each of the 24 subjects performed 52 handling steps resulting in a total of 1248 evaluated handling steps. |
3 hours | |
Primary | Nasa Task Load Index (N-TLX) | The operating procedure of the device consists of multiple tasks comprising several handling steps. the subjects were asked about the task load in six different dimensions in the standardized N-TLX. Task load is a hypothetical construct that represents the cost incurred by a human operator to achieve a particular level of performance. The dimensions of the N-TLX are mental, physical and temporal demands as well as performance, effort and frustration in the task. Each dimension is evaluated on a 20-point scale. This scale is then transferred to the task load index, which is a scale between 0 and 100 points. Workload levels below 50 were perceived as acceptable. | 3 hours | |
Primary | Observation of technique | Here the observations of technique errors were discussed with the subjects in order to identify the specific causes. In this interview, the subjects were also asked for their feedback on the general ease of use of the device. | 3 hours. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02763410 -
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
|
||
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Suspended |
NCT04589065 -
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
|
N/A | |
Completed |
NCT03806998 -
Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
|
Phase 3 | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
Completed |
NCT02116270 -
Accelerated Immunosenescence and Chronic Kidney Disease
|
N/A | |
Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
Completed |
NCT01388270 -
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
|
Phase 4 | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01187953 -
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacroâ„¢ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
|
Phase 3 | |
Completed |
NCT01008631 -
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers
|
N/A | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Recruiting |
NCT00470769 -
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR
|
N/A | |
Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 |